LeMaitre Vascular (NASDAQ:LMAT) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of LeMaitre Vascular (NASDAQ:LMATFree Report) from a hold rating to a buy rating in a research note issued to investors on Wednesday.

Separately, JMP Securities started coverage on LeMaitre Vascular in a research report on Monday, October 23rd. They issued an outperform rating and a $60.00 target price on the stock. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of Moderate Buy and an average price target of $67.60.

Check Out Our Latest Stock Report on LeMaitre Vascular

LeMaitre Vascular Stock Performance

NASDAQ:LMAT opened at $58.04 on Wednesday. The stock’s 50-day simple moving average is $55.73 and its 200 day simple moving average is $55.40. The company has a market cap of $1.29 billion, a P/E ratio of 47.97, a P/E/G ratio of 2.88 and a beta of 0.84. LeMaitre Vascular has a 52-week low of $44.27 and a 52-week high of $68.67.

LeMaitre Vascular (NASDAQ:LMATGet Free Report) last released its earnings results on Wednesday, November 1st. The medical instruments supplier reported $0.33 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.31 by $0.02. The business had revenue of $47.40 million for the quarter, compared to the consensus estimate of $47.58 million. LeMaitre Vascular had a return on equity of 9.83% and a net margin of 14.69%. LeMaitre Vascular’s quarterly revenue was up 21.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.25 earnings per share. As a group, equities analysts predict that LeMaitre Vascular will post 1.34 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 24,869 shares of the business’s stock in a transaction that occurred on Thursday, December 7th. The stock was sold at an average price of $54.71, for a total transaction of $1,360,582.99. Following the transaction, the chief executive officer now owns 2,312,857 shares of the company’s stock, valued at $126,536,406.47. The sale was disclosed in a document filed with the SEC, which is available through this link. In other news, CEO George W. Lemaitre sold 22,288 shares of the company’s stock in a transaction that occurred on Monday, December 11th. The stock was sold at an average price of $54.42, for a total value of $1,212,912.96. Following the transaction, the chief executive officer now owns 2,269,475 shares of the company’s stock, valued at $123,504,829.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO George W. Lemaitre sold 24,869 shares of the company’s stock in a transaction that occurred on Thursday, December 7th. The shares were sold at an average price of $54.71, for a total value of $1,360,582.99. Following the completion of the transaction, the chief executive officer now directly owns 2,312,857 shares in the company, valued at approximately $126,536,406.47. The disclosure for this sale can be found here. Company insiders own 12.50% of the company’s stock.

Hedge Funds Weigh In On LeMaitre Vascular

Several institutional investors and hedge funds have recently made changes to their positions in LMAT. Altshuler Shaham Ltd bought a new position in LeMaitre Vascular during the 2nd quarter worth $29,000. Captrust Financial Advisors grew its holdings in shares of LeMaitre Vascular by 555.3% during the 1st quarter. Captrust Financial Advisors now owns 616 shares of the medical instruments supplier’s stock worth $29,000 after purchasing an additional 522 shares in the last quarter. BluePath Capital Management LLC bought a new position in shares of LeMaitre Vascular in the third quarter worth $31,000. FMR LLC increased its position in shares of LeMaitre Vascular by 111.7% in the first quarter. FMR LLC now owns 633 shares of the medical instruments supplier’s stock worth $33,000 after purchasing an additional 334 shares during the period. Finally, DekaBank Deutsche Girozentrale bought a new position in shares of LeMaitre Vascular in the third quarter worth $38,000. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

(Get Free Report)

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers restoreflow allografts; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system.

Read More

Analyst Recommendations for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.